Market News AIOpen the app

Tempus AI is teaming up with AstraZeneca in a new deal worth $200 million over five years.

DealRead the original at SEC EDGAR
Good for TEM

Tempus AI gained a 5-year customer commitment for $200 million in fees, including a $32 million yearly minimum. AstraZeneca may terminate, but must cover any unpaid shortfall, making the agreement favorable for Tempus.

TEM · Tempus AI, Inc.

AI read · Good for TEM

The AI's read

The fees can give Tempus a steadier stream of customer income across current and future products. The annual spending target is $40 million, but that is a target, not the yearly minimum. AstraZeneca can still end the agreement, yet must pay any shortfall against its total commitment.

AZN · AstraZeneca AB

AI read · Neutral

The connection

AstraZeneca committed to $200 million in fees and received extended collaborator benefits, and can end the deal but may still owe a shortfall. The filing does not value those benefits, so it shows no clear change to AstraZeneca's outlook.

Get alerts for TEM

Follow Tempus AI, Inc. (TEM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TEM
Free on the App Store and Google Play, or on the web.